Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Biotechnology Cancer Cures -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (113)	9/11/1999 11:36:00 PM
From: tnsaf	Read Replies (1) \| Respond to of 226

An interesting item from Bioresearch online. The first bit and link... Jason ---------------------------- Inhibiting p53 May Improve Chemotherapy Outcome 9/9/99 In what might be considered a bold or foolish move, depending on your point of view, scientists from the University of Illinois, Chicago (UIC) and Quark Biotechnologies (Pleasanton, CA) have shut down p53 in mice, and have shown that doing so can protect normal tissues from radiation damage. While the loss of p53 is generally thought to be bad news?over 50% of human tumors lack this protein, whose function is believed to be to rid the body of damaged cells through apoptosis?this group reasoned that its absence might also spare cells from the ravages of radiation and chemotherapy. Work reported in the September 10 issue of Science indicates that their thinking is correct. Mice whose p53 was inhibited withstood lethal doses of radiation, and showed no ill effects of the treatment?that is, no increased incidence of tumors?months after treatment. ---------------------------- www2.bioresearchonline.com{8FCA4AC7-62DC-11D3-9A60-00A0C9C83AFB}&Bucket=Latest+Headlines

To: scaram(o)uche who wrote (113)	9/16/1999 1:41:00 AM
From: chirodoc	Respond to of 226

September 15, 1999 11:23....CTI Files First FDA Module OGDEN, Utah, Sept. 15 /PRNewswire/ -- Computerized Thermal Imaging Inc. (OTC Bulletin Board: COII) announced today that it has submitted its first data package to the FDA as part of its application for Pre Market Approval (PMA) of its breast cancer detection system. "This is an exciting announcement," said David A. Packer, CTI's president. "The submission of data to the FDA is a very important milestone. Although we have worked with the FDA for some time, this begins the official review process. Under the Modular approach, each module is individually reviewed and approved by the FDA. We will be working closely with the FDA as they review this data. Successful completion of this process will allow the CTI System to be introduced to the market and accepted more readily. We are pushing forward as quickly as good science permits" In April, the FDA approved CTI's use of the new modular approach to submitting an application for Pre-Market Approval (PMA). Under this approach, CTI's PMA application has been broken into modules, each containing a portion of the data needed for FDA review. The preparation of Module 2 is already well underway with the remaining modules to be submitted in a timely fashion. Further announcements are planned as the various modules are completed and filed. CTI is seeking FDA approval for the use of the Computerized Thermal Imaging System as an adjunctive diagnostic test to the mammogram and clinical examination for the detection of breast cancer. The system uses a sophisticated heat sensitive camera to record thermal images of breast tissue, which are processed by proprietary computer algorithms. The test is simple, painless and involves no radiation, breast compression, electrodes or electrical current.